VECTORITE BIOMEDICAL INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.4 TWD | -0.61% |
|
+7.19% | -23.19% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 940.6 | 625.8 | 492 | 621.1 | 621.1 | 934.5 |
| Enterprise Value (EV) 1 | 860.6 | 530.7 | 402.4 | 381.8 | 407.6 | 730.8 |
| P/E ratio | -31 x | -6.93 x | -6.06 x | 73 x | -23.3 x | -142 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 4.56 x | 23.6 x | 20 x | 21.6 x | 14.5 x | 16.7 x |
| EV / Revenue | 4.17 x | 20 x | 16.4 x | 13.3 x | 9.5 x | 13.1 x |
| EV / EBITDA | -15.6 x | -8.26 x | -9.42 x | -14.7 x | -18.8 x | -105 x |
| EV / FCF | -5.73 x | -12.6 x | -15 x | -33.4 x | -20.6 x | -77.7 x |
| FCF Yield | -17.5% | -7.96% | -6.66% | -2.99% | -4.85% | -1.29% |
| Price to Book | 2.81 x | 2.19 x | 1.43 x | 1.33 x | 1.41 x | 2.17 x |
| Nbr of stocks (in thousands) | 25,569 | 25,569 | 34,670 | 43,772 | 43,772 | 43,771 |
| Reference price 2 | 36.79 | 24.47 | 14.19 | 14.19 | 14.19 | 21.35 |
| Announcement Date | 4/22/19 | 4/29/20 | 4/29/21 | 4/29/22 | 4/28/23 | 4/25/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 206.3 | 26.54 | 24.54 | 28.77 | 42.91 | 55.85 |
| EBITDA 1 | -55.28 | -64.24 | -42.72 | -25.94 | -21.68 | -6.972 |
| EBIT 1 | -68 | -82.73 | -60.93 | -42.43 | -30.54 | -16.13 |
| Operating Margin | -32.96% | -311.69% | -248.24% | -147.47% | -71.16% | -28.88% |
| Earnings before Tax (EBT) 1 | -29.08 | -99.94 | -71.69 | 8.329 | -26.45 | -6.628 |
| Net income 1 | -30.32 | -90.27 | -68.17 | 8.358 | -26.41 | -6.601 |
| Net margin | -14.7% | -340.11% | -277.75% | 29.05% | -61.55% | -11.82% |
| EPS 2 | -1.187 | -3.530 | -2.340 | 0.1945 | -0.6098 | -0.1508 |
| Free Cash Flow 1 | -150.2 | -42.22 | -26.8 | -11.42 | -19.78 | -9.408 |
| FCF margin | -72.79% | -159.09% | -109.2% | -39.69% | -46.09% | -16.84% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/22/19 | 4/29/20 | 4/29/21 | 4/29/22 | 4/28/23 | 4/25/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 80 | 95.1 | 89.6 | 239 | 214 | 204 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -150 | -42.2 | -26.8 | -11.4 | -19.8 | -9.41 |
| ROE (net income / shareholders' equity) | -8.33% | -29.5% | -20.9% | 2.05% | -5.82% | -1.52% |
| ROA (Net income/ Total Assets) | -8.59% | -13.7% | -10% | -6.15% | -3.98% | -2.2% |
| Assets 1 | 353 | 656.8 | 678.6 | -135.8 | 663.2 | 300.5 |
| Book Value Per Share 2 | 13.10 | 11.20 | 9.940 | 10.70 | 10.10 | 9.830 |
| Cash Flow per Share 2 | 3.130 | 4.510 | 0.8300 | 0.9000 | 0.6400 | 0.5800 |
| Capex 1 | 13.2 | 4.31 | 0.77 | 1.8 | 0.89 | 4.76 |
| Capex / Sales | 6.41% | 16.22% | 3.14% | 6.24% | 2.07% | 8.51% |
| Announcement Date | 4/22/19 | 4/29/20 | 4/29/21 | 4/29/22 | 4/28/23 | 4/25/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -23.19% | 22.07M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- 4170 Stock
- Financials Vectorite Biomedical Inc.
